618462-47-8

Upstream product

• 618462-36-5 (3R,6S)-1-Benzyl-3-[3-((2R,5S)-4-benzyl-6-ethoxy-5-isopropyl-3-oxo-2,3,4,5-tetrahydro-pyrazin-2-yl)-propyl]-3-(3-chloro-propyl)-5-ethoxy-6-isopropyl-3,6-dihydro-1H-pyrazin-2-one 
• 433735-04-7 1-[(3'R,6'S)-1'-benzyl-5'-ethoxy-3',6'-dihydro-6'-isopropylpyrazin-3'-yl-2'-one]-3-[(3''R,6''S)-1''-benzyl-5''-ethoxy-3'',6''-dihydro-6''-isopropylpyrazin-3''-yl-2''-one]propane 
• 618462-37-6 (3S,8aR)-2-Benzyl-8a-[3-((2R,5S)-4-benzyl-6-ethoxy-5-isopropyl-3-oxo-2,3,4,5-tetrahydro-pyrazin-2-yl)-propyl]-3-isopropyl-hexahydro-pyrrolo[1,2-a]pyrazine-1,4-dione 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

Unusual peptides containing the 2,6-diaminopimelic acid framework: Stereocontrolled synthesis, X-ray analysis, and computational modelling. Part 2

The stereocontrolled synthesis of peptides 6, 9 and 14, structural variants of 2,6-diaminopimelic acid, was carried out starting from the chiral synthon 1, easily obtained from L-valine. The configuration of the introduced stereogenic centres has been ass